Thymosin Alpha-1 (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Twice weekly is the standard cadence for most chronic indications, given subcutaneously into the abdomen, thigh, or upper arm with sites rotated between injections. The sepsis protocol is a clinical setting exception that loads with twice daily dosing for 5 days, then steps down to once daily. No cycling protocol is established; published trials dose continuously for the treatment course, typically 12 to 24 weeks, with hepatitis trials often running 24 weeks or longer and autoimmune course length varying by context. TA1 is positioned as an immune educator rather than rescue therapy, so timing matters more than dose: it performs when the immune system is dysregulated but still recoverable, and ICU COVID cases with organ failure showed no consistent benefit because that window had already closed.

Results Timeline

Sequence described in the research record. Individual response varies.

• Sepsis protocol only, days 1 to 5: 1.6 mg twice daily as a loading phase.
• Sepsis protocol only, after day 5: step down to 1.6 mg once daily.
• Chronic indications, weeks 1 to 24: 1.6 mg twice weekly, continuous, with no cycling break built in.
• Week 24 and beyond: hepatitis trials typically ran 24 weeks or longer; immune modulation in autoimmune contexts varies in length.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 1.6 mg = 16 units (0.16 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store frozen at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 plus months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Keep the vial protected from light and inspect the solution before each draw; discard if cloudy or discolored.

Supplies Needed

Planned on a full 24 week course at 1.6 mg twice weekly, which is 3.2 mg per week across 2 injections.

Peptide Vials (Thymosin Alpha-1, 10 mg vial):

• A 24 week course uses 76.8 mg total, which is about 8 vials of 10 mg; a 12 week course uses 38.4 mg, or about 4 vials.

Insulin Syringes (U-100):

• Per week: 2 syringes, U-100, 50 unit barrel preferred for a 16 unit draw.
• Full 24 week course: 48 syringes; a full year at this cadence is about 96.

Bacteriostatic Water (10 mL bottles):

• 1.0 mL per 10 mg vial, so one 10 mL bottle covers about 10 vials, which is more than a full 24 week course needs.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the skin.
• Full 24 week course: 96 swabs across 48 injections; about 200 per year, or two 100 count boxes.

Important Notes

Practical considerations for consistency and safety.

• TA1 is an immune educator, not a stimulator or a suppressor. It expands regulatory T-cells rather than suppressing inflammatory cells, so the immune system gets smarter rather than quieter.
• Timing matters more than dose. The 1.6 mg figure is consistent across protocols, so indication selection and how early the course starts drive the result; once organ failure has occurred, the window for immune re-education has closed.
• Context dependent behavior is the most unusual property on record. Renga 2020 found IDO1 dependent tolerance in gut tissue but not in tumor microenvironments, where CD8+ T-cell infiltration instead increased and Tregs decreased.
• Contraindications: organ transplant recipients are the principal exclusion, since immunomodulatory activity could conflict with the immunosuppressive regimen that prevents rejection. Pregnancy and breastfeeding lack safety data, and active severe immune dysregulation calls for medical supervision.
• Stacking context: KPV for direct NF-kB inhibition, BPC-157 for gut tissue repair, NAD+ as an energy substrate for immune expansion, Selank for cortisol normalization, and VIP for broad tissue tolerance. In the Immune Peptide Protocol, KPV calms inflammation first and TA1 is the Phase 3 centerpiece that rebuilds regulatory architecture afterward.
• Regulatory Note: Thymosin Alpha-1 is not FDA approved in the United States. The synthetic form, thymalfasin (Zadaxin), is approved in 35 plus countries including Italy, Singapore, and China for chronic hepatitis B and C. US orphan drug designation covers melanoma, hepatitis, and DiGeorge syndrome, and US compounding access was under regulatory review as of late 2024 through PCAC proceedings, where TA1 was removed from the Category 2 list when the original nominator withdrew. The source material states no WADA classification.

How This Works

Four interconnected mechanisms carry the effect. First, T-cell maturation: TA1 enhances maturation of immature T-lymphocytes, promoting proper receptor expression and restoring functional capacity in exhausted or dysfunctional cells, which is closer to quality control than indiscriminate boosting. Second, Treg expansion: Li 2014 showed in rheumatoid arthritis models that TA1 suppressed Th17 pro-inflammatory responses while expanding CD4+CD25+Foxp3+ regulatory T-cells, tipping the Th17/Treg seesaw toward regulation by addition rather than by suppression. Third, the IDO1 pathway (indoleamine 2,3-dioxygenase 1): Romani 2007 showed TA1 activates dendritic cells through TLR-9/TRIF signaling and promotes IDO1 expression, establishing a tolerogenic environment in local tissue where dendritic cells begin training new Tregs instead of arming attack cells. Fourth, selective cytokine control: IL-6 and TNF-alpha go down, IFN-gamma is preserved or enhanced so antiviral defense stays intact, and IL-10 goes up to support repair. The most remarkable finding is the context dependence documented by Renga 2020, where TA1 promoted IDO1 dependent tolerance specifically in gut tissue in DSS and TNBS colitis models while not activating that same pathway in tumor microenvironments; at tumor sites CD8+ T-cell infiltration increased and Tregs decreased, giving tolerance where it is needed and surveillance where it is needed. TA1 also amplifies endogenous antioxidant enzymes including catalase, SOD, and glutathione peroxidase, which compounds with the anti-inflammatory effect since chronic inflammation generates substantial oxidative stress.

Benefits & Side Effects

Observations from the published record.

• T1 chronic hepatitis B: Yang 2013 meta-analysis found TA1 plus antivirals gave superior virological response versus antivirals alone, roughly 40.6% complete virological response at 1.6 mg subcutaneous twice weekly; Liu 2020 confirmed the combination with PEG-IFN.
• T1 sepsis: a Chinese multicenter RCT reported roughly 9% lower mortality in the TA1 group using 1.6 mg subcutaneous twice daily for 5 days, then once daily.
• T2 COVID-19 and Long COVID: early and moderate disease showed improved lymphocyte recovery and reduced progression to severe illness, while ICU cases with organ failure showed no consistent benefit. In PASC, a University of Rome Tor Vergata open study found restored naive B and T cells, with the greatest benefit in those who had more severe acute illness.
• T2 to T3 autoimmune and T3 gut: Pica 2016 measured median serum TA1 of 18.38 ng/ml in autoimmune patients versus 53.08 ng/ml in healthy controls (p<0.0001), with psoriatic arthritis most depleted at 6.93 ng/ml. Renga 2020 showed IDO1 dependent colitis protection in mouse models, but that work comes from a single research group with no independent replication and zero human IBD trials.
• Side effects across 11,000 plus trial subjects are mild: injection site reactions such as redness and soreness, occasional transient flu-like symptoms including low-grade fever and mild fatigue that resolve within hours, and no major safety signals or consistent drug interaction pattern.
• What is not documented: broad immunosuppression, consistent infection risk elevation, HPTA suppression, a withdrawal pattern, or rebound dysregulation. Other named gaps include no human IBD trial, no TA1 plus biologics co-administration data, no microbiome interaction data, and no head to head comparison against conventional immunosuppressants.

Lifestyle Factors

Complementary strategies for best outcomes.

• Sleep 7 to 9 hours. Immune regulation and Treg expansion happen substantially during sleep, so sleep debt works directly against the protocol; untreated sleep apnea drives chronic IL-6 elevation for the same reason.
• Reduce chronic stress. Cortisol opposes the Treg expansion TA1 promotes, which is also why Selank is named as a cortisol and immune bridge when anxiety is part of the picture.
• Address gut health first. If barrier function is compromised, ongoing antigenic load keeps driving systemic inflammation and TA1 cannot outpace it. Omega-3 fatty acids support the IL-10 pattern TA1 promotes.
• Limit alcohol during the course, since ethanol metabolism generates ROS and challenges immune balance, and consider entering TA1 after acute inflammation is already calmed, with NAD+ alongside as an energy substrate for metabolically demanding Treg proliferation.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Garaci E et al. Thymosin alpha-1 bench to bedside review (Int Immunopharmacol, 2012).
2. Romani L et al. TA1 activates dendritic cell tryptophan catabolism, IDO1 tolerance pathway (Blood, 2007).
3. Li J et al. TA1 suppresses Th17 and promotes Tregs in rheumatoid arthritis (Int Immunopharmacol, 2014).
4. Renga G et al. TA1 protects from CTLA-4 intestinal immunopathology, gut specific IDO1 tolerance with tumor surveillance preserved (Life Sci Alliance, 2020).
5. Yang Y et al. Thymalfasin in chronic hepatitis B meta-analysis, roughly 40.6% virological response (J Viral Hepat, 2013).
6. Pica F et al. Serum TA1 levels depleted in chronic inflammatory autoimmune diseases (Clin Exp Immunol, 2016).